Drug Profile

Research programme : adapter chimeric antigen engineered NK-92 cells - Miltenyi Biotec

Alternative Names: (AdCAR)-engineered NK-92 cells - Miltenyi Biotec; AdCAR NK-92

Latest Information Update: 28 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Miltenyi Biotec GmbH
Class CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Oct 2023 No recent reports of development identified for preclinical development in Solid-tumours in Germany (Parenteral)
09 Jun 2022 Preclinical trials in Acute myeloid leukaemia in Germany (Parenteral)
09 Jun 2022 Pharmacodynamics data from a preclinical trials in Acute myeloid leukaemia presented at the 27th Congress of the European Haematology Association (EHA-2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com